Fisetin Benefits: What the Evidence Actually Shows

Fisetin has a longer list of claimed benefits than its human evidence currently justifies.

It is described as a senolytic, antioxidant, anti-inflammatory compound, brain-protective flavonoid, longevity supplement, metabolic aid, cardiovascular protector, skin-rejuvenating compound and even a potential hair-growth agent. Almost every one of those claims has some scientific basis.

But they do not all have the same kind of evidence.

That distinction matters because fisetin has produced unusually interesting results in cells, isolated human tissues and multiple animal models. Human research has also moved further than many older articles suggest. We now have randomized human studies in several disease-specific settings, observational senescence-biomarker data, pharmacokinetic research and ongoing trials designed specifically around healthy aging and cellular senescence.

The results are mixed. Some studies have produced encouraging biomarker or condition-specific signals. Others have been negative, inconclusive or too small to answer the question convincingly. No human trial has yet shown that fisetin extends lifespan, reverses aging, prevents dementia or reliably clears senescent cells throughout the body.

The most accurate summary in 2026 is simple: fisetin has substantial biological and preclinical evidence, but its broad clinical benefits in humans are still being established.

For the broader evidence hierarchy, dosing, safety and formulation context, start with our complete fisetin guide.

Find the evidence for your specific question: senescent-cell clearance; joint pain and inflammation; muscle and frailty; brain and cognition; blood pressure; skin; and hair growth and grey hair. This article brings the outcomes together; the focused reviews examine mechanisms, studies and endpoints in detail.

Fisetin benefits at a glance: what is actually supported?

The fastest way to understand fisetin is to separate human outcomes from human biomarkers, animal findings and cell-level mechanisms. A pathway can be real without producing a meaningful clinical benefit.

Claimed benefit	Best evidence available	What the evidence currently supports
Senescent-cell clearance	Strong cell and mouse evidence; ex vivo human tissue; small uncontrolled human biomarker signal	Credible senotherapeutic activity, but systemic senolysis has not been proven in living humans
Healthy aging / healthspan	Strong preclinical rationale; human aging trials underway	Promising research target, not an established human healthspan intervention
Longer lifespan	One influential positive mouse study; later multi-site NIA mouse study found no significant lifespan effect	No human lifespan evidence; animal lifespan findings are inconsistent
Inflammation	Small human biomarker trials plus extensive preclinical research	Biologically plausible, with early human signals; broad clinical anti-inflammatory benefit remains unproven
Brain protection / cognition	Extensive animal literature; one condition-specific acute stroke RCT	No strong evidence that routine supplementation improves cognition in healthy or aging adults
Muscle / frailty	Strong recent mouse research; human trials in progress	Preclinical benefit awaiting clinical confirmation
Knee osteoarthritis	Completed randomized placebo-controlled human trial	No consistent clinical benefit across the reported outcomes
Bone health	Randomized human study with a very small fisetin subgroup	Inconclusive
Vascular aging	Recent mouse and mechanistic work; human trial underway	Not established as a human cardiovascular treatment
Metabolic health / weight	Animal research plus one small 2026 randomized trial in men with obesity, reported in multiple publications	Early human signals exist, but replication and fisetin-only effects remain uncertain
Skin aging	Cells, human skin grafts on mice and animal models	Promising preclinical biology; no controlled anti-aging outcome trial in people
Hair growth	Keratinocyte and mouse experiments	Preclinical only
Cancer	Extensive laboratory literature; one small colorectal-cancer biomarker RCT	Not proven to prevent or treat cancer

Why can fisetin appear to have so many potential benefits?

Fisetin is a naturally occurring flavonol found in foods such as strawberries, apples, persimmons, grapes, onions and cucumbers. Its scientific interest extends well beyond simple antioxidant chemistry. Fisetin interacts with cellular systems involved in oxidative stress, inflammation, mitochondrial function, cell survival and stress responses.

The feature that made fisetin especially interesting to longevity researchers is its senotherapeutic activity. Senescent cells are cells that have stopped dividing in response to stress or damage. Senescence can be useful in normal biology, including wound healing and tumor suppression, but some senescent cells persist and develop a pro-inflammatory secretory profile known as the senescence-associated secretory phenotype, or SASP.

A senolytic selectively eliminates susceptible senescent cells. A senomorphic changes harmful properties of senescent cells, such as their inflammatory secretions, without necessarily killing them. Fisetin may show both kinds of activity depending on the experimental system.

That helps explain why the compound appears in research on aging, joints, muscle, blood vessels, cognition and metabolic disease. But acting on many biological pathways does not automatically mean that taking a supplement produces many proven health benefits.

For the mechanism itself, see our evidence review of fisetin as a senolytic. For the broader chemistry and background, see what fisetin is and how it works.

1. Fisetin and senescent “zombie” cells

This is the best-known fisetin claim and the one with the strongest experimental foundation.

In the landmark 2018 study by Yousefzadeh and colleagues, researchers screened multiple flavonoid polyphenols against senescent cells. Fisetin showed particularly strong senotherapeutic activity in the models tested. The investigators then moved into animal experiments, where fisetin reduced several markers associated with cellular senescence and improved multiple measures of late-life health in mice. Ex vivo experiments using human adipose tissue also supported activity against some senescent cell populations. ^[1]

There is an important limitation hidden inside the phrase “fisetin clears zombie cells”: senescent cells are heterogeneous. A senescent fibroblast, endothelial cell, immune cell, chondrocyte or adipose progenitor does not necessarily use the same survival pathways. A compound can behave as a senolytic in one cell population and have a weaker or different effect in another.

So the most defensible claim is not that fisetin indiscriminately clears every senescent cell. It is that fisetin has demonstrated selective senotherapeutic activity in several laboratory and animal systems.

Do we have evidence of senolysis in living humans?

We have an early signal, not definitive proof.

A 2024 human study evaluating senescence-associated biomarkers included a small observational subgroup of people who reported taking 100 mg of fisetin daily between study visits. Several circulating markers associated with aging and the SASP decreased, and the proportion of strongly C12FDG-positive peripheral blood mononuclear cells fell. ^[2]

That is interesting, but it was not a randomized placebo-controlled fisetin efficacy trial. The group was small, supplement use was not experimentally assigned and a change in circulating blood-cell markers does not establish that senescent cells were cleared from muscle, arteries, brain, joints or other tissues.

This is why “fisetin is a senolytic” and “taking fisetin has been clinically proven to clear senescent cells throughout the human body” are not equivalent statements.

2. Healthy aging, healthspan and longevity

The senolytic hypothesis naturally leads to a bigger question: could fisetin improve healthspan or lifespan?

In mice, the answer is interesting enough to justify serious research. The 2018 study reported that late-life fisetin treatment reduced age-related pathology and increased median and maximum lifespan in one experiment. Later work has added tissue-specific findings relevant to muscle function and vascular aging. ^[1]

But fisetin has not consistently extended lifespan even in mice.

The National Institute on Aging Interventions Testing Program later evaluated fisetin in genetically heterogeneous UM-HET3 mice across its multi-site testing framework. Under the dose and schedule used in that program, fisetin did not significantly extend lifespan in either sex. ^[3]

That negative result does not prove that every possible dose, schedule or formulation would fail. It does, however, materially weaken the simple claim that fisetin is a proven lifespan-extending compound.

No human study has shown that fisetin extends lifespan. Human trials are only now testing more direct aging-related endpoints such as inflammation, senescence markers, frailty, physical performance and cognition.

3. Inflammation and SASP signaling

Fisetin has extensive anti-inflammatory activity in cell and animal models. Research has reported effects on NF-κB and MAPK signaling, oxidative-stress systems and multiple cytokines. Senescence biology provides another route: reducing senescent-cell burden or altering the SASP could theoretically reduce inflammatory signaling.

The human evidence is smaller, but it is no longer accurate to say that no human data exist.

The colorectal-cancer randomized trial

A small double-blind randomized placebo-controlled trial enrolled 37 people with colorectal cancer receiving chemotherapy. Participants received either 100 mg/day of fisetin or placebo for seven weeks. Several inflammatory markers decreased within the fisetin group, but the crucial comparison is fisetin versus placebo. On that comparison, the change in IL-8 was statistically significant, while several other measured factors were not significantly different between groups. ^[4]

This is legitimate human evidence that fisetin may influence an inflammatory biomarker in a specific clinical population. It is not proof that fisetin broadly lowers chronic inflammation in otherwise healthy adults.

Negative clinical evidence also matters

In a placebo-controlled crossover screening study in Gulf War illness, fisetin did not significantly improve overall symptom severity at the tested doses. ^[5]

That result illustrates a recurring problem in supplement interpretation: a compound can affect inflammatory pathways in experimental systems without producing a noticeable clinical effect in a particular disease.

The important distinction is between biological anti-inflammatory activity and demonstrated improvements in symptoms or disease outcomes. Mechanistic pathway evidence is informative, but it should not be mistaken for proof of a broad clinical anti-inflammatory benefit.

4. Brain health, cognition and neurological protection

The preclinical neurological literature is one of fisetin’s deepest research areas.

Fisetin has been studied in animal models involving learning and memory, neuroinflammation, amyloid biology, oxidative stress and neurological injury. In a transgenic Alzheimer’s-disease mouse model, long-term fisetin administration preserved learning and memory performance and altered several inflammatory and stress-response pathways. ^[6]

That does not establish a dementia-prevention benefit in humans.

There is currently no strong randomized clinical evidence showing that routine oral fisetin supplementation improves memory, attention or cognition in healthy older adults.

The acute ischemic-stroke trial is real human evidence—but a different question

A double-blind randomized placebo-controlled clinical trial tested fisetin as an adjunct to recombinant tissue plasminogen activator in people being treated for acute ischemic stroke. Researchers reported better neurological scores in some delayed-treatment strata and lower circulating MMP-2, MMP-9 and CRP. ^[7]

This is condition-specific human clinical evidence. It is also a hospital-based acute intervention used alongside thrombolytic treatment. It does not show that an over-the-counter fisetin supplement prevents stroke, prevents Alzheimer’s disease or makes a healthy person think more clearly.

For that distinction in detail, see fisetin for brain health and cognition.

5. Muscle, frailty and physical function

This is one of the more compelling recent areas of fisetin research, although the strongest evidence remains preclinical.

A 2025 Aging Cell study treated old mice intermittently with fisetin and compared the effects with genetic clearance of p16-positive senescent cells and the experimental senolytic navitoclax. Fisetin attenuated age-related changes in frailty and grip strength and reduced skeletal-muscle expression of several senescence-related genes. The same improvements were not seen in young mice, which is consistent with an intervention targeting biology that accumulates with age. ^[8]

That is strong translational evidence, but it remains a mouse study.

Human programs are now testing whether the same biology translates into measurable changes in frailty and physical function. Until controlled results are available, claims that fisetin “preserves muscle,” “reverses frailty” or “improves strength” in older people remain ahead of the evidence.

For the translational trial pipeline and the distinction between frailty, muscle preservation and bodybuilding claims, see fisetin for muscle preservation and frailty.

6. Arthritis, joint pain and bone health

Osteoarthritis is a logical target for senolytic research because senescent chondrocytes and inflammatory signaling are implicated in cartilage degeneration. Cell experiments have shown anti-inflammatory effects of fisetin in human osteoarthritis chondrocytes, and mouse studies have reported improvements in experimental osteoarthritis. ^[11]

Importantly, this area has progressed beyond animal models.

The randomized knee-osteoarthritis trial

A phase I/II randomized, double-blind, placebo-controlled study tested intermittent fisetin in people with mild-to-moderate symptomatic knee osteoarthritis. The regimen was based on the high-dose intermittent senolytic approach used in translational research. Results did not show a consistent fisetin advantage across pain, physical-function, strength, gait, imaging and biomarker outcomes. ^{[9] [29]} The published 2025 meeting abstract reports 74 randomized participants, while the registry lists 75 enrolled; it is a second source for the same trial, not a separate clinical replication.

This is important negative evidence. It shows why promising chondrocyte and mouse findings should not automatically be converted into a claim that fisetin relieves human arthritis.

Bone health remains inconclusive

Fisetin was also included in a randomized skeletal-health study in older women. The fisetin subgroup contributing to several analyses was very small, and the available results did not establish a clear improvement in bone-turnover, bone-density or senescence-related outcomes. ^[10]

The correct conclusion is neither “fisetin improves bone health” nor “fisetin has been proven ineffective for bone.” The human evidence is simply too limited and imprecise.

For the full human osteoarthritis, inflammatory-marker and mechanistic evidence, see fisetin for inflammation and joint pain.

7. Cardiovascular and vascular aging

Claims about “heart health” often combine blood pressure, endothelial function, arterial stiffness, atherosclerosis and ischemic injury as if they were the same endpoint. They are not.

Recent preclinical work is particularly interesting for vascular aging. In old mice, intermittent fisetin has been reported to reduce senescence-associated signaling and improve aspects of endothelial dysfunction. Other work in premature vascular-aging models has linked fisetin with lower vascular senescence, altered SASP expression and improvements in endothelial function and aortic stiffness. ^{[12] [13]}

These experiments provide a coherent mechanistic rationale. They are not human cardiovascular outcome trials.

Human vascular studies are underway, but fisetin should not currently be presented as a proven treatment for hypertension, arterial stiffness or cardiovascular disease. Our dedicated fisetin and blood-pressure review owns that question.

8. Metabolic health, insulin resistance and weight

This section has changed meaningfully in 2026.

Older summaries could accurately say that metabolic claims were almost entirely based on rodent research. That is no longer the whole story.

Animal studies have reported effects on insulin resistance, hepatic steatosis, inflammatory signaling, glucose handling and adipose or liver fibrosis. Those findings are still important because they provide the mechanistic foundation. ^[14]

But a small randomized human trial in men with obesity has now begun to test fisetin directly.

A 2026 randomized trial reported early metabolic signals

A double-blind parallel-group randomized controlled trial assigned 60 sedentary men with obesity to placebo, fisetin at 200 mg/day, exercise training plus placebo, or exercise training plus fisetin for 12 weeks. The investigators reported significant between-group differences in body weight and several adipokine and inflammatory outcomes. The fisetin-only group showed greater weight loss than placebo, while the combined exercise-plus-fisetin group produced the broadest changes across several measured biomarkers. Only the combined group showed a statistically significant BMI reduction versus placebo in the reported post-hoc analysis. ^[15]

A companion 2026 publication from the same underlying four-arm randomized trial reported additional outcomes involving Maresin-1, inflammatory markers, fasting glucose, insulin and HOMA-IR. ^[16] These two publications report different outcomes from one trial; they are not independent replication.

These publications are worth including because they move fisetin’s metabolic evidence beyond mice, but they represent one randomized trial rather than two independent studies. They do not justify calling fisetin a proven weight-loss supplement.

The trial was small, population-specific and closely tied to structured exercise interventions. Several endpoints were secondary or exploratory, and the findings have not yet been independently replicated in a large trial. It is also too early to know whether the reported weight and biomarker effects are durable or clinically meaningful.

So the 2026 conclusion is more nuanced than “no human evidence”:

Fisetin now has early human metabolic and body-weight signals, but the evidence is still too limited to establish fisetin as a treatment for obesity, insulin resistance or type 2 diabetes.

9. Skin aging and hair growth

Both claims come from real experimental research. Neither is a demonstrated consumer benefit in humans.

Skin

Researchers have studied fisetin in senescent human dermal fibroblasts and in older human skin grafted onto immunodeficient mice. In those experimental systems, fisetin reduced senescent-cell burden and altered collagen and SASP-related measures. ^[17]

The human origin of the skin makes the experiment more biologically relevant than a simple immortalized cell line, but it is still not a clinical trial in which people took fisetin and were assessed for wrinkles, elasticity, hydration or visible skin aging.

For that topic, see fisetin for skin.

Hair

Fisetin has also affected TERT expression and signaling relevant to hair-follicle biology in keratinocyte models. Mouse experiments reported accelerated entry into the anagen growth phase and increased hair growth. ^[18]

Human efficacy has not been demonstrated, and there is no controlled clinical evidence showing that oral fisetin reverses grey hair. Those claims belong in the preclinical column.

See fisetin for hair growth and grey hair for the full evidence review.

10. Cancer research: substantial laboratory activity, no proven treatment

Fisetin has a large laboratory cancer literature. Researchers have studied its effects on proliferation, apoptosis, cell-cycle control, angiogenesis, metastasis and signaling pathways across numerous cancer-cell models.

But killing cancer cells in culture is a much lower evidentiary bar than safely treating cancer in a person.

The small colorectal-cancer trial discussed earlier measured inflammatory biomarkers during chemotherapy. It did not establish tumor regression, cancer prevention, progression-free survival or overall survival benefits. ^[4]

Fisetin therefore has legitimate anticancer research interest, but it is not an established cancer treatment and should not be used as a substitute for surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy or other evidence-based cancer care.

What do the human fisetin studies actually show?

Separate conference evidence: A May 2026 meeting abstract reported exploratory lung-function and selected quality-of-life findings from a 10-person randomized pilot in CVID-associated GLILD. This early report is not a full completed trial publication, and no reliable clinical benefit or systemic human senolysis can be concluded from it [28].

The human evidence is now large enough to require separation by study type. A September 2026 clinical-translation review identified 34 registered fisetin-related clinical studies; at its 14 August 2026 registry search, six were completed and four had results available. Importantly, several trials use fisetin inside multi-ingredient products or multimodal programs, so they cannot be treated as evidence for fisetin alone. [22]

Human evidence class	Examples	What it currently supports	Main limitation
Published direct fisetin trials	Colorectal-cancer adjunct, stroke adjunct, Gulf War illness, 2026 obesity/metabolic trial	Human exposure and some disease-specific biomarker or functional signals	Small studies, different populations/endpoints; no general longevity conclusion
Completed direct fisetin registry studies	Knee osteoarthritis, skeletal health, FITCATS carpal tunnel, mild-Alzheimer’s pilot	Additional human safety/feasibility and condition-specific data	Null, inconclusive, uncontrolled, very small, or results not yet posted depending on the study
Ongoing direct fisetin trials	Fisetin HIGH, Fisetin LOW, AFFIRM, FIRST, TROFFi, PROFFi, REVITALiSE, OLD AIR	Tests PK, senescence biomarkers, frailty, mobility, sarcopenia, vascular and respiratory outcomes	No efficacy conclusion before results
Combination/proprietary interventions containing fisetin	ELDERDIET, AppleX, BBH-1001, urolithin A + fisetin, BMAC/losartan studies	Shows fisetin is being studied in broader intervention strategies	Any benefit may come from other ingredients or co-interventions
Human pharmacokinetics	Unformulated vs hybrid-hydrogel fisetin; FISEKIN-1	Confirms low oral exposure and tests formulation, age and food effects	Exposure does not equal clinical benefit

The overall picture is therefore more nuanced than either “fisetin has no human evidence” or “human trials prove its benefits.” Human exposure is real, the trial pipeline is active, and a few condition-specific signals exist. What remains missing is reproducible evidence that fisetin alone improves a general healthspan outcome or produces systemic senescent-cell clearance in humans.

Why does promising mouse research not automatically translate to people?

Humans are not large mice

Lifespan, metabolism, immune function, disease progression and senescent-cell populations differ across species. Even within mice, genetic background, sex, age and treatment schedule can alter the response.

There is no universal senescent cell

Senescence is a state, not one cell type. Different senescent populations express different markers, produce different SASP profiles and rely on different survival pathways. A senolytic can therefore work in one tissue or model and disappoint in another.

Cell-culture exposure is not the same as swallowing a capsule

Cells in a dish can be exposed directly to controlled fisetin concentrations. Oral fisetin must survive digestion, intestinal absorption, first-pass metabolism, conjugation and tissue distribution.

Formulation changes exposure dramatically

In a randomized crossover pharmacokinetic study in 15 healthy volunteers, a fenugreek-galactomannan hybrid-hydrogel fisetin formulation produced dramatically higher plasma exposure than unformulated fisetin. ^[19]

That proves that formulation can alter pharmacokinetics. It does not prove that the higher-exposure product clears more senescent cells, extends lifespan or produces superior health outcomes.

For the absorption question, see fisetin bioavailability and liposomal fisetin.

The optimal dosing strategy is still unresolved

Human studies use very different approaches. Some test relatively low daily exposure. Others use short, high-dose intermittent regimens intended to create a “hit-and-run” senolytic effect.

No rigorous head-to-head human trial has established which strategy produces better long-term outcomes. That uncertainty is why dosing decisions should be separated from claims about benefits. See fisetin dosage and fisetin pulse dosing and the Mayo Clinic protocol.

What benefits are not currently proven?

As of September 2026, fisetin is not proven in humans to:

• extend lifespan;
• reverse biological aging;
• prevent Alzheimer’s disease;
• prevent or cure cancer;
• reliably clear senescent cells throughout the body;
• reverse grey hair;
• regrow human hair;
• rejuvenate visibly aged human skin;
• treat type 2 diabetes;
• treat obesity as a stand-alone weight-loss therapy;
• lower blood pressure as an established treatment; or
• eliminate arthritis.

“Unproven” does not mean that every hypothesis is false. It means the evidence has not reached the point where these outcomes should be stated as established benefits.

Which fisetin studies could change the answer next?

Several current programs address different parts of the translation problem rather than repeating one standard protocol.

Direct fisetin studies

Fisetin HIGH tests short high-dose exposure in healthy volunteers and older adults with multimorbidity, with pharmacokinetic, safety and senescence-related endpoints. [21]

Fisetin LOW tests 100 mg/day for seven weeks in adults aged 50 and older, with suPAR and broader aging-related outcomes. [20]

REVITALiSE directly tests weight-based intermittent fisetin versus usual care in older adults with sarcopenia, using walk speed, grip strength, physical activity and muscle-biopsy outcomes. [23]

FIRST tests intermittent fisetin in peripheral artery disease with 6-minute walk distance plus tissue and blood senescence-related markers. [24]

TROFFi, PROFFi, AFFIRM and SEN-SURVIVORS extend the physical-function and frailty program into older women and cancer-survivor populations. Their designs differ enough that they should not be described as one interchangeable “Mayo protocol.”

Large or proprietary combination studies

ELDERDIET is unusually large—4,000 planned participants—but combines fisetin with intermittent fasting and a more intensive Mediterranean-diet intervention, so it will test the package rather than fisetin alone. [25]

AppleX tests a whole-apple polyphenol extract standardized to fisetin, while another study tests fisetin alone and combined with urolithin A. These are useful formulation and combination experiments, but any outcome must be attributed to the tested product or arm—not automatically to pure fisetin.

Are fisetin supplements proven to provide these benefits?

No. Evidence for the molecule should not automatically be transferred to every product that contains the word “fisetin” on its label.

Supplements can differ in chemical purity, dose, excipients, dissolution, stability and systemic exposure. A pharmacokinetic study of one enhanced-delivery formulation does not validate every liposomal, nano, powder or generic capsule formulation.

That distinction becomes especially important when a product claim relies on a mouse dose, a cell-culture concentration or a proprietary delivery system that has never been tested for the clinical outcome being advertised.

Product-quality and buying questions belong in the best fisetin supplement guide, not in the scientific benefits claim itself.

What about safety?

Human safety data are growing, but they remain much thinner than the popularity of fisetin supplementation might suggest. Short-term studies have used both daily and intermittent regimens, while major ongoing clinical programs include active safety monitoring.

There is still no large multi-year randomized safety database for chronic high-dose fisetin supplementation in the general population. Medication interactions, pregnancy, breastfeeding, cancer treatment, anticoagulation and complex medical conditions deserve separate consideration.

For those questions, see fisetin side effects and safety and fisetin drug interactions.

Does fisetin work?

The answer depends on what “work” means.

Fisetin clearly has biological activity. It interacts with pathways involved in cellular senescence, inflammation, oxidative stress and stress responses. It produces functional effects in multiple animal models, and human studies now include both positive and negative findings.

What has not been established is the broad consumer promise often attached to the molecule.

There is no single general health benefit that has been demonstrated repeatedly across large, high-quality human randomized trials. The scientific case is strongest for senescence biology, inflammation/SASP modulation and several age-related functional effects in animal models. Human translation is still being tested.

That makes fisetin neither a proven anti-aging drug nor an evidence-free fad. It is a serious experimental geroscience compound whose clinical value remains unresolved.

The bottom line on fisetin benefits

Fisetin deserves the scientific attention it receives, but the strongest reason is not that every advertised benefit has been proven.

The compound has unusually broad preclinical evidence. The 2018 senotherapeutic work established a strong foundation, and later studies have extended the case into skeletal muscle, vascular aging, neurological models, metabolism, skin and other tissues. Human evidence has also expanded to include randomized trials, pharmacokinetic studies and early senescence-associated biomarker data.

But human results are not uniformly positive.

The knee-osteoarthritis trial did not show a consistent clinical benefit. The skeletal-health fisetin group was too small to establish efficacy. Gulf War illness results were negative. Positive findings in acute stroke and colorectal-cancer patients arose in highly specific clinical settings. New obesity-related publications from a small randomized trial are encouraging enough to update the evidence map, but not mature enough to establish fisetin as a metabolic or weight-loss treatment.

And the biggest longevity questions remain unanswered: whether fisetin meaningfully reduces senescent-cell burden across human tissues, improves healthspan, extends lifespan, and what dose or formulation would best achieve those effects.

For now, the most defensible description is this: fisetin is a promising senotherapeutic compound with strong preclinical evidence, early and mixed human findings, and no proven human longevity benefit yet.